CoChat
Sign Up
Cited by 441Cancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease PrognosisFerroptosis and cancer prognosis

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Open access
Valero, Cristina, Lee, Mark, Hoen, Douglas, Weiss, Kate, Kelly, Daniel W., Adusumilli, Prasad S., Paik, Paul K., Plitas, George, Ladanyi, Marc, Postow, Michael A., Ariyan, Charlotte E., Shoushtari, Alexander N., Balachandran, Vinod P., Hakimi, A. Ari, Crago, Aimee M., Long Roche, Kara C., Smith, J. Joshua, Ganly, Ian, Wong, Richard J., Patel, Snehal G., Shah, Jatin P., Lee, Nancy Y., Riaz, Nadeem, Wang, Jingming, Zehir, Ahmet, Berger, Michael F., Chan, Timothy A., Seshan, Venkatraman E., Morris, Luc G. T.·2021·Nature Communications
DOI 10.1038/s41467-021-20935-9PMC PMC7851155
Open this paper in CoChat — free accountOpen PDF

Abstract

Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit for a wide range of cancer types. Because only a subset of patients experience clinical benefit, there is a strong need for biomarkers that are easily accessible across diverse practice settings. Here, in a retrospective cohort study of 1714 patients with 16 different cancer types treated with ICI, we show that higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall and progression-free survival, and lower rates of response and clinical benefit, after ICI therapy across multiple cancer types. Combining NLR with tumor mutational burden (TMB), the probability of benefit from ICI is significantly higher (OR = 3.22; 95% CI, 2.26-4.58; P < 0.001) in the NLR low/TMB high group compared to the NLR high/TMB low group. NLR is a suitable candidate for a cost-effective and widely accessible biomarker, and can be combined with TMB for additional predictive capacity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-20935-9

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pan-cancer outcomes based on neutrophil-to-lymphocyte ratio (NLR). a Overall survival, b progression-free survival, c response, and d clinical benefit at a pan-cancer level based on high vs. low NLR. The cutoff was the top 20th percentile within each cancer type. P-values are according to log-rank test for a and b, and Pearson’s χ2-test for c and d.
Fig. 1 Pan-cancer outcomes based on neutrophil-to-lymphocyte ratio (NLR). a Overall survival, b progression-free survival, c response, and d clinical benefit at a pan-cancer level based on high vs. low NLR. The cutoff was the top 20th percentile within each cancer type. P-values are according to log-rank test for a and b, and Pearson’s χ2-test for c and d.CC BY · PubMed Central
Fig. 2 Outcomes based on neutrophil-to-lymphocyte ratio (NLR) stratified by cancer type. Forest plots showing hazard ratios (HRs) with 95% CIs for a overall survival and b progression-free survival across cancer types, comparing top 20th NLR percentile within each cancer type to bottom 80th. HRs were calculated with Cox proportional hazard regression. Abreviations: OS, overall survival; Haz. Ratio, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; PFS, progression-free survival.
Fig. 2 Outcomes based on neutrophil-to-lymphocyte ratio (NLR) stratified by cancer type. Forest plots showing hazard ratios (HRs) with 95% CIs for a overall survival and b progression-free survival across cancer types, comparing top 20th NLR percentile within each cancer type to bottom 80th. HRs were calculated with Cox proportional hazard regression. Abreviations: OS, overall survival; Haz. Ratio, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; PFS, progression-free survival.CC BY · PubMed Central
Fig. 3 Pan-cancer outcomes according to a combined neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB) categorization. a Overall survival, b progression-free survival, c response, and d clinical benefit at a pan-cancer level. Patients were classified into four categories based on NLR low/high and TMB low/high, using median within cancer type as cutoff for both variables. P-values are according to log-rank test for a and b, and Pearson’s χ2-test for c and d.
Fig. 3 Pan-cancer outcomes according to a combined neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB) categorization. a Overall survival, b progression-free survival, c response, and d clinical benefit at a pan-cancer level. Patients were classified into four categories based on NLR low/high and TMB low/high, using median within cancer type as cutoff for both variables. P-values are according to log-rank test for a and b, and Pearson’s χ2-test for c and d.CC BY · PubMed Central
Fig. 4 Outcomes across quartile-based categories of neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB). Heat maps of hazard ratios (HRs) for a overall survival and b progression-free survival, and heat maps of odds ratios (ORs) for c response and d clinical benefit based on 16 within cancer type quartile-based categories of NLR and TMB. HRs were calculated with Cox proportional hazard regression. ORs were calculated with logistic regression.
Fig. 4 Outcomes across quartile-based categories of neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB). Heat maps of hazard ratios (HRs) for a overall survival and b progression-free survival, and heat maps of odds ratios (ORs) for c response and d clinical benefit based on 16 within cancer type quartile-based categories of NLR and TMB. HRs were calculated with Cox proportional hazard regression. ORs were calculated with logistic regression.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Amin, M. B. et al. AJCC Cancer Staging Manual (Springer, 2017).

Cited by

Sorted by citations

See all 441

Related

See all

Metadata

Authors
Valero, C., Lee, M., Hoen, D., Weiss, K., Kelly, D. W., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., Ariyan, C. E., Shoushtari, A. N., Balachandran, V. P., Hakimi, A. A., Crago, A. M., Long Roche, K. C., Smith, J. J., Ganly, I., Wong, R. J., Patel, S. G., Shah, J. P., Lee, N. Y., Riaz, N., Wang, J., Zehir, A., Berger, M. F., Chan, T. A., Seshan, V. E., & Morris, L. G. T.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
  • Chan, Timothy A.
  • Seshan, Venkatraman E.
  • Morris, Luc G. T.
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2021-02-01
Volume
12
Issue
1
Pages
729-729
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-021-20935-9
PMC
PMC7851155
OpenAlex
W3127371144
Cited by
441
References
57
Citations by year
2026: 53 · 2025: 74 · 2024: 116 · 2023: 92 · 2022: 80 · 2021: 26
FWCI
28.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fundación Alfonso Martín Escudero (N/A)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA205426, R35 CA232097)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
immune checkpoint inhibitors, neutrophil-to-lymphocyte ratio, tumor mutational burden, predictive biomarkers, tumor response, overall survival, progression-free survival, cancer immunotherapy, prognostic factors
MeSH terms
Progression-Free Survival, Immune Checkpoint Inhibitors, Aged, Female, Follow-Up Studies, Humans, Lymphocytes, Male, Middle Aged, Neoplasms, Neutrophils, Predictive Value of Tests, Retrospective Studies, Lymphocyte Count, Drug Resistance, Neoplasm, Mutation Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review